{"public_id":"cl_2c1a2f41b48bdff0cdbc9791d0186a1b","status":"active","superseded_by_public_id":null,"corpus_id":16963349,"text":"Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade results in complete control of tumors in a majority of mice and immunity to further tumor inoculation in the K7M2 mouse model of metastatic osteosarcoma.","confidence":0.95,"paper":{"corpus_id":16963349,"title":"Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","url":"https://sah.borca.ai/papers/16963349"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_2efbd3b6f8b86c0b729c967aaed4526a","name":"α-PD-L1 antibody blockade","description":"Antibody that blocks PD-L1, used in combination with α-CTLA-4 in this study.","types":["antibody","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_2efbd3b6f8b86c0b729c967aaed4526a"},{"public_id":"co_34da2c3181ad1f09b70b68647d1353eb","name":"α-CTLA-4","description":"Antibody that blocks CTLA-4, used in combination with α-PD-L1 in this study.","types":["antibody","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_34da2c3181ad1f09b70b68647d1353eb"},{"public_id":"co_4c6db59d5aabdbdba7da6f1a8dd8f212","name":"K7M2 mouse model","description":"An implantable mouse model of metastatic osteosarcoma used to evaluate combination immunotherapy.","types":["animal model"],"url":"https://sah.borca.ai/concepts/co_4c6db59d5aabdbdba7da6f1a8dd8f212"},{"public_id":"co_64453ef1105fabd755cf007847119fa9","name":"combination immunotherapy","description":"Therapeutic approach combining α-CTLA-4 and α-PD-L1 antibody blockade to block multiple inhibitory pathways.","types":["treatment strategy"],"url":"https://sah.borca.ai/concepts/co_64453ef1105fabd755cf007847119fa9"},{"public_id":"co_a615979b66670440fee36a85d004c9be","name":"metastatic osteosarcoma","description":"A common bone cancer in children that spreads to the lungs, studied in the K7M2 mouse model.","types":["cancer type"],"url":"https://sah.borca.ai/concepts/co_a615979b66670440fee36a85d004c9be"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_2c1a2f41b48bdff0cdbc9791d0186a1b"}